Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23147699 | 0.83 | ALDH1A1 (0.49) | NAMPTHRH3ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL30222191 | 0.83 | ALDH1A1 (0.49) | NAMPTHRH3ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL12367667 | 0.82 | HRH3 (0.46) | NAMPTHRH3ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2004014 | 0.80 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2893597 | 0.80 | ALDH1A1 (0.46) | NAMPTHRH3ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL12367604 | 0.79 | OPRK1 (0.42) | OPRK1NAMPTLIPEKCNH2 | |
| SCHEMBL16702162 | 0.79 | NAMPT (0.45) | NAMPTLIPE | |
| SCHEMBL14721607 | 0.79 | ALDH1A1 (0.45) | NAMPTHRH3ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL5534680 | 0.79 | OPRK1 (0.59) | OPRK1NAMPTHRH3KCNH2 | |
| SCHEMBL15571843 | 0.78 | HTR2A (0.38) | OPRK1HRH3ALDH1A1KDM4ELIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | AZI2, GPR119, GID4 | OPRK1 252/4885NAMPT 2261/4885HRH3 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.